Landmark Analysis Shows Continuous Treatment With REVLIMID(R) Plus Dexamethasone Significantly Increases Overall Survival In Multiple Myeloma Patients
Celgene International SÃ rl (NASDAQ: CELG) announced that data from a landmark analysis of patients with relapsed/refractory multiple myeloma found that continuous treatment with REVLIMID (lenalidomide) in combination with dexamethasone after achieving best response resulted in significantly longer overall survival and increased time to disease progression compared to those who discontinued treatment after ten months or less.
More: continued here
Filed under: Blood on December 11th, 2008